Biological Products, (No Diagnostic Substances)
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| Stonepine Capital Management, LLC | 1.62M | $2.0M | 16.49% | +961.1K | 2026-06-30 |
| Alyeska Investment Group, L.P. | 944.3K | $1.0M | 9.58% | -- | 2026-06-30 |
| FRANKLIN RESOURCES INC | 914.5K | $1.0M | 9.28% | -- | 2026-06-30 |
| 683 Capital Management, LLC | 724.6K | $1.0M | 7.35% | -- | 2026-06-30 |
| VANGUARD CAPITAL MANAGEMENT LLC | 88.9K | -- | 0.90% | -- | 2026-06-30 |
| BIOS Capital Management, LP | 81.0K | -- | 0.82% | -86.8K | 2026-06-30 |
| GEODE CAPITAL MANAGEMENT, LLC | 72.5K | -- | 0.74% | -13.7K | 2026-06-30 |
| CITADEL ADVISORS LLC | 63.1K | -- | 0.64% | +38.3K | 2026-06-30 |
| OPPENHEIMER & CO INC | 63.0K | -- | 0.64% | +39.0K | 2026-06-30 |
| VANGUARD FIDUCIARY TRUST CO | 43.6K | -- | 0.44% | -- | 2026-06-30 |
